Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab versus mepolizumab in relapsing or refractory EGPA
NL-OMON53511Phase 3Recruiting
- Sponsor
- GSK
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing Depemokimab + standard of care with Mepolizumab + standard of care (2 arms). Primary endpoint: Remission at Week 36 and Week 52. Started Jul 2023; status: recruiting.
02
Drugs
depemokimabmepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NL-OMON53511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53511.